Skip to main content

InflaRx N.V.

corporate_fare Company Profile

InflaRx N.V.

IFRX·NASDAQ·Life Sciences·CIK 0001708688

We are a biopharmaceutical company that uses our own technologies to find, develop, and sell new, powerful, and specific drugs that block the complement activation factor called C5a and its receptor C5aR. The complement system is a key part of the body's natural immune system, protecting it by identifying and removing harmful agents like bacteria and viruses. When the complement system is fully activated, C5 is broken down, releasing C5a, which then acts through its receptor C5aR. This full activation can also happen directly through natural enzymes in the body that are not part of the complement system. Our drug candidates, vilobelimab and izicopan (previously known as INF904), are designed to target C5a and its receptor C5aR. This allows us to specifically stop the strong inflammatory response seen in many autoimmune and other inflammatory diseases, which is triggered by C5a/C5aR activation. The complement system's main job is to help the body fight invading microorganisms by quickly creating inflammation and producing factors that kill pathogens and bring immune cells to infected areas. Activating the complement system ultimately produces C5a and C5b from complement factor C5. C5a, by binding to the C5a receptor C5aR1, creates an inflammatory environment by attracting and strongly activating neutrophils and by causing various cell types to produce molecules that promote inflammation. The C5a/C5aR1 signaling pathway is central to this process and a critical part of the innate immune system. While these inflammatory responses normally help fight infection, too much or uncontrolled C5a, as seen in certain diseases, can severely damage the body's own tissues, contributing to many autoimmune and inflammatory diseases.

InflaRx N.V. (NASDAQ:IFRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for IFRX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • InflaRx Receives Nasdaq Delisting Warning for Sub-$1.00 Share Price
  • InflaRx Cuts 30% Workforce, Restructures to Extend Cash Runway to Mid-2027 and Focus on Izicopan

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
€29.33K EUR
Net Income
-€45.63M EUR
Diluted EPS
-€0.68 EUR
Op. Cash Flow
-€35.31M EUR
Free Cash Flow
-€35.43M EUR
Gross Profit
-€7.24M EUR
Cash & Equivalents
€1.28M EUR
Debt / Equity
0.00×
Net Margin
-1555.82×
Source: 20-F · filed 2026-03-20 · accession 0001213900-26-032065

Insider Transactions

IFRX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$1.02 -1.92% today
52-week range · as of 2026-11-03 $0.7984 – $2.95
Market cap
$153.26M
Volume
472.1K (0.4× avg)
3-mo avg 1.1M
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IFRX - Filings & News (Page 2)

IFRX
Mar 13, 2026, 6:10 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.946
Real-time Price: $1.02 info
Change: +$0.074 (+8%) info
Market Cap: $153.263M info
IFRX
Jan 08, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.09
Real-time Price: $1.02 info
Change: -$0.070 (-6%) info
Market Cap: $153.263M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets